glp 1 gip gcg receptor agonist GLP-1R, GIPR, and GCGR: Targets for Obesity and Diabetes GLP-1 Genetics: How Genes Affect

End Points The primary end points were the association between GLP-1 RAs and the risk of incident DR, NAION, or sight-threatening complications over a 2-year follow-up period

Holman RR, et al

8 Based on data from the MAESTRO-NASH trial, resmetirom demonstrated histological benefits with a number needed to treat of five for the resolution of MASH and 8.5 for fibrosis regression, 9 thus posing significant economic challenges

This expansion is fueled by a growing healthcare sector, a large target patient population, and significant unmet clinical needs for diabetes and obesity treatments

Presented at Scientific Sessions of the ADA Meeting (2013)

To qualify, you generally need: A BMI of 30 or higher, or 27 or higher with a weight-related condition A prior trial of an oral weight-loss medication such as Qsymia or Contrave that did not work or that you cannot take At least 6 months of attempted weight loss through diet and exercise A prior authorization from your prescriber documenting medical necessity For type 2 diabetes, TRICARE coverage of GLP-1s like Ozempic and Mounjaro is more straightforward, though prior authorization may still apply